A treatment that slows worsening can sound less dramatic than one that restores what has been lost. For lecanemab, that distinction is central: in a major trial, people with early Alzheimer’s disease declined more slowly on average than those given placebo, but their disease did not stop progressing.
Who the evidence applies to
Lecanemab received traditional FDA approval in 2023 for people with early Alzheimer’s disease, including mild cognitive impairment or mild dementia, with confirmed amyloid plaques. The evidence does not establish the same benefit for people at later stages or for memory problems from other causes. Identifying the right stage and confirming amyloid are therefore part of the treatment question, not administrative details.
A modest difference matters
The medicine is an antibody that targets amyloid, a protein that accumulates in the brains of people with Alzheimer’s. In the clinical trial, treatment slowed the average pace of cognitive and functional decline over 18 months compared with placebo. That group-level result can matter to patients and families, but it does not predict exactly what one person will experience.
The risks are part of the story
Lecanemab can cause amyloid-related imaging abnormalities, or ARIA, which may involve brain swelling or small areas of bleeding. Some cases have no symptoms, while others can be serious, so treatment involves clinical assessment and MRI monitoring. These risks, along with the need for ongoing infusions, are essential context when weighing the trial’s measured benefit.
What remains unanswered
Researchers are still learning how durable the benefit is, which patients are most likely to benefit, and how treatment fits into care over longer periods. The result is important because it shows that targeting amyloid can alter the course of decline to a degree—not because it reverses Alzheimer’s or removes the need for careful decisions. A headline about a new drug should leave room for both facts.